Contact Us

Contact Us

Please contact us below with any questions

+44 (0)33 3321 2371

Side Contact
COVID-19 Rapid Antigen Lateral Flow Tests in Stock in UK and Available to Buy - More Info
quadratech Logo
{{ toggleHam ? 'CLOSE' : 'MENU' }}
Next Day & International Delivery
Competitive Pricing
Knowledgeable Sales Team
Based In The UK

Article of Interest (Coagulation) – Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

Abstract AIMS:

AIMS:This open-label, two-period, randomized, crossover study was designed to determine the effect of CYP2C19 reduced function variants on exposure to active metabolites of, and platelet response to, prasugrel and clopidogrel.

METHODS: Ninety healthy Chinese subjects, stratified by CYP2C19 phenotype, were mg for 10mg or clopidogrel 75 randomly assigned to treatment with prasugrel 10 days followed by 14 day washout and 10 day treatment with the other drug. Eighty-three subjects completed both treatment periods. Blood samples were collected at specified time points for measurement of each drug’s active metabolite (Pras-AM and Clop-AM) concentrations and determination of inhibition of platelet aggregation (IPA) by light transmittance aggregometry. CYP2C19 genotypes were classified into three predicted phenotype groups: rapid metabolizers [RMs (*1/*1)], heterozygous or intermediate metabolizers [IMs (*1/*2, *1/*3)] and poor metabolizers [PMs (*2/*2, *2/*3)].

RESULTS: Pras-AM exposure was similar in IMs and RMs (90% CI 0.85, 1.03) and slightly lower in PMs than IMs (90% CI 0.74, 0.99), whereas Clop-AM exposure was significantly lower in IMs compared with RMs (90% CI 0.62, 0.83), and in PMs compared with IMs (90% CI 0.53, 0.82). IPA was more consistent among RMs, IMs and PMs in prasugrel treated subjects (80.2%, 84.2% and 80.2%, respectively) than in clopidogrel treated subjects (59.7%, 56.2% and 36.8%, respectively; P < 0.001).

CONCLUSIONS: Prasugrel demonstrated higher active metabolite exposure and more consistent pharmacodynamic response across all three predicted phenotype groups compared with clopidogrel, confirming observations from previous research that CYP2C19 phenotype plays an important role in variability of response to clopidogrel, but has no impact on response to prasugrel.

REFERENCE:Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Kelly RP et al, Br J Clin Pharmacol. 2012 Jan;73(1):93-105.

Cookie Consent

Cookies help us deliver our services. By using our services, you agree to our use of cookies.